The Swiss startup rewriting how the world pays for medicine - one value-based contract at a time.
For decades, the price of a drug and the value it delivered were two separate conversations. A payer signed a contract, the manufacturer shipped the product, and whether the therapy actually helped patients rarely touched the invoice. Lyfegen, a health-tech company founded in Basel in 2018, was built on the premise that those two conversations should be one.
The company builds software that lets health insurers, governments, hospital payers, pharmaceutical firms and medical device makers design, track and settle value-based agreements - contracts where reimbursement is tied to real-world outcomes, not volume alone. In practice, that means automating the tangle of claims, rebates and settlement terms that has historically been managed in spreadsheets, meetings and prayer.
Its mission is stated plainly: "Make healthcare more efficient and affordable by providing access, pricing, and rebate solutions." The vision underneath it is larger - to "improve patient lives by driving the world's transition to value- and data-driven healthcare."
"Make healthcare more efficient and affordable by providing access, pricing, and rebate solutions." — Lyfegen, company mission
Lyfegen was co-founded by Girisha Fernando (CEO), Michel Mohler (CFO) and Nico Mros (CXO). Fernando spent roughly nine years at Roche working across market access, pricing and IT before leaving - at 29 - to build the company. He had watched from the inside as promising therapies stalled behind pricing that no one could operationalize.
That background matters. Value-based contracting is not a marketing idea at Lyfegen; it is a set of deeply technical problems - claims validation, rebate calculation, morphology, adherence, settlement logic - that the founding team had lived. The company's expertise sits at the intersection of health economics, drug pricing and software engineering, and its stack reflects that: React, Node, TypeScript, PostgreSQL, Neo4j graph data, and AI tooling including Langchain.
Headquartered in Basel - a global pharma capital - Lyfegen occupies an unusual position: it sits next door to the industry it holds accountable, serving the payers who negotiate against it.
"Improve patient lives by driving the world's transition to value- and data-driven healthcare." — Lyfegen, company vision
Complex drug agreements generate obligations that are hard to track. Rebates are owed on conditions - outcomes achieved, thresholds crossed, volumes met - and reconciling them by hand is slow, error-prone and expensive. Lyfegen says its platform has identified up to 30% of total rebates that were being missed, and cut cross-functional administrative costs by up to 97%.
The deeper problem is structural. Value-based healthcare is endorsed at every conference and executed almost nowhere, because the shift is operational, not philosophical. You cannot pay for outcomes you cannot measure, and you cannot manage contracts you cannot see. Lyfegen's wager is that building the measurement and management layer is what finally lets the model spread.
A secure repository that consolidates agreements, claims and invoices, auto-assessing claims against 4,500+ contracting agreements across 20 pricing models.
End-to-end managed service that tracks agreements and identifies, calculates and collects rebates on a client's behalf.
Model complex pricing scenarios in real time - pack detail, settlement, adherence, tax - and compare outcomes before signing.
The world's largest repository of value-based and public drug pricing deals: 7,000+ agreements, 33 countries, 550+ drugs, 150+ manufacturers.
Assess historical rebate and contract performance to inform the next round of negotiations.
An AI assistant that helps users navigate dense agreements, pricing models and platform data.
Lyfegen runs a B2B SaaS model, licensing its access, pricing and rebate platform to insurers, governments, hospitals and pharma - with a managed-service option for clients who prefer to outsource the work entirely. Value is framed around money recovered and administrative burden removed.
The company has publicly likened its role to Airbnb's: it doesn't make the medicine any more than Airbnb builds hotels. It builds the trusted layer between payers and manufacturers that makes an outcome-based agreement trackable, auditable and fast. Where competitors are often in-house spreadsheets, consultancy-built models, or point tools bundled inside larger pharma-services vendors, Lyfegen's differentiator is data depth: the Agreements Library gives clients a benchmark no single manufacturer or payer could assemble alone.
Its platform tracks more than $1B in pharmaceutical revenue and manages over $0.5B in rebates annually across 4,000+ agreements. — Lyfegen, reported platform metrics
More than 50 healthcare organizations across eight markets in Europe, North America and the Middle East rely on Lyfegen. Named users include Johnson & Johnson, Pfizer, Swiss insurer Sympany and health fund EGK-Gesundheitskasse. In one flagship deployment, Lyfegen enabled a value-based contract between J&J Medical Devices and a leading Swiss hospital, tying reimbursement to patient outcomes.
It sits in the market access and health-economics layer of the healthcare stack - between the pharmaceutical companies that price therapies and the payers that fund them. As gene and cell therapies push list prices into the millions, the pressure to pay based on results rather than promises grows, and that is precisely the wave Lyfegen is built to ride.
Lyfegen has raised more than $22M since founding, without changing its core pitch. The market simply caught up to it.
Fernando, Mohler and Mros launch Lyfegen HealthTech AG to digitize value-based drug pricing.
An early CHF 750K funds the value-based contracting software.
Additional funding fuels product build-out and first payer deployments.
Oversubscribed round led by aMoon Fund with APEX Ventures scales the platform internationally.
Agreements Library surpasses 7,000 public deals; LyfegenGPT and AI features launch.
TX Ventures leads a further round to scale rebate management globally.
It builds software that helps insurers, governments, hospitals, pharma and medtech firms manage value-based drug pricing and rebate agreements - automating claims, tracking rebates and simulating pricing scenarios.
Girisha Fernando (CEO), Michel Mohler (CFO) and Nico Mros (CXO) founded it in Basel, Switzerland in 2018.
Over 50 healthcare organizations across eight markets, including Johnson & Johnson, Pfizer, Sympany and EGK-Gesundheitskasse. The platform tracks more than $1B in pharma revenue and $0.5B in rebates annually.
More than $22M total, including an $8M Series A (2022) led by aMoon Fund and a CHF 5M extension (December 2024) led by TX Ventures.
It ties the price paid for a drug or device to the health outcomes it delivers, rather than volume alone. Lyfegen provides the software to design, track and settle these outcome-based agreements.